title: Ca2+ channel actions of the non-dihydropyridine Ca2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries.
abstract: We studied the membrane effects of (1S,2S)-2-(2-[[3-2(benzimidazolyl) propyl]methylamino]ethyl)-6-fluoro-1, 2,3,4-tetrahydro-1-isopropyl-2-naphthyl-methoxyacetate dihydrochloride, Ro 40-5967, a new non-dihydropyridine (DHP) Ca2+ channel antagonist, on dog coronary and saphenous arterial vascular muscle cells using the whole-cell patch-clamp method. Long-lasting (L-type) inward currents in 20 mM Ba2+ were measured over a range of test potentials (300 ms) from -50 mV to +90 mV from a holding potential of -80 mV in the presence of 1 microM Bay k8644 (a DHP Ca2+ agonist). Ro 40-5967 caused a concentration-dependent suppression of Ca2+ channel currents in muscle cells from both arteries, with greater potency on coronary than saphenous arterial cells. The concentration of Ro 40-5967 which inhibited the magnitude of peak inward currents by 50% (IC50) was estimated to be 1 microM (n = 5) in muscle cells from coronary artery and 10 microM (n = 4) in saphenous artery. Ro 40-5967 (1 microM) decreased the amplitude of the activation current-voltage relationship for coronary L-type Ca2+ channel currents over a wider range of membrane potentials than verapamil, diltiazem, or nifedipine. In contrast, block of Ca2+ channel currents in saphenous artery cells by 1 microM Ro 40-5967 was only observed at command potentials positive to 0 mV. Ro 40-5967 (1 microM) significantly shifted the voltage-inactivation curve downward by 40% in coronary (n = 4), but only by 18% in saphenous arterial muscle cells (n = 3).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Earle A. Chiles Research Institute, Oregon Health Sciences University, Portland 97201.
authors.forename: K
authors.initials: K
authors.lastname: Bian
authors.forename: K
authors.initials: K
authors.lastname: Hermsmeyer
mesh_terms: D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000502:physiology*; D002478:Cells, Cultured; D004285:Dogs; D004594:Electrophysiology; D008564:Membrane Potentials / Q000187:drug effects; D020748:Mibefradil; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000502:physiology; D013764:Tetrahydronaphthalenes / Q000494:pharmacology*
chemical_list: D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D013764:Tetrahydronaphthalenes; D020748:Mibefradil; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester